FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327831237> ?p ?o ?g. }

• W4327831237 endingPage "101912" @default.
• W4327831237 startingPage "101912" @default.
• W4327831237 abstract "Isoniazid preventive therapy (IPT) initiation during pregnancy was associated with increased incidence of adverse pregnancy outcomes in the TB APPRISE trial. Effects of in utero IPT exposure on infant growth are unknown.This post-hoc analysis used data from the TB APPRISE trial, a multicentre, double-blind, placebo-controlled trial, which randomised women to 28-week IPT starting in pregnancy (pregnancy-IPT) or postpartum week 12 (postpartum-IPT) in eight countries with high tuberculosis prevalence. Participants were enrolled between August 2014 and April 2016. Based on modified intent-to-treat analyses, we analysed only live-born babies who had at least one follow-up after birth and compared time to infant growth faltering between arms to 12 weeks and 48 weeks postpartum in overall and sex-stratified multivariable Cox proportional hazards regression. Factors adjusted in the final models include sex of infant, mother's baseline BMI, age in years, ART regimen, viral load, CD4 count, education, and household food insecurity.Among 898 HIV-exposed uninfected (HEU) infants, 447 (49.8%) were females. Infants in pregnancy-IPT had a 1.47-fold higher risk of becoming underweight by 12 weeks (aHR 1.47 [95% CI: 1.06, 2.03]) than infants in the postpartum-IPT; increased risk persisted to 48 weeks postpartum (aHR 1.34 [95% CI: 1.01, 1.78]). Maternal IPT timing was not associated with stunting or wasting. In sex-stratified analyses, male infants in the pregnancy-IPT arm experienced an increased risk of low birth weight (LBW) (aRR 2.04 [95% CI: 1.16, 3.68), preterm birth (aRR 1.81 [95% CI: 1.04, 3.21]) and becoming underweight by 12 weeks (aHR 2.02 [95% CI: 1.29, 3.18]) and 48 weeks (aHR 1.82 [95% CI: 1.23, 2.69]). Maternal IPT timing did not influence growth in female infants.Maternal IPT during pregnancy was associated with an increased risk of LBW, preterm birth, and becoming underweight among HEU infants, particularly male infants. These data add to prior TB APPRISE data, suggesting that IPT during pregnancy impacts infant growth, which could inform management, and warrants further examination of mechanisms.The TB APPRISE study Supported by the National Institutes of Health (NIH) (award numbers, UM1AI068632 [IMPAACT LOC], UM1AI068616 [IMPAACT SDMC], and UM1AI106716 [IMPAACT LC]) through the National Institute of Allergy and Infectious Diseases, with cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (contract number, HHSN275201800001I) and the National Institute of Mental Health." @default.
• W4327831237 created "2023-03-19" @default.
• W4327831237 creator A5002278563 @default.
• W4327831237 creator A5003846337 @default.
• W4327831237 creator A5005879554 @default.
• W4327831237 creator A5012262637 @default.
• W4327831237 creator A5012318863 @default.
• W4327831237 creator A5013215019 @default.
• W4327831237 creator A5013790590 @default.
• W4327831237 creator A5015964057 @default.
• W4327831237 creator A5018284836 @default.
• W4327831237 creator A5020589345 @default.
• W4327831237 creator A5022150988 @default.
• W4327831237 creator A5024408755 @default.
• W4327831237 creator A5028771001 @default.
• W4327831237 creator A5031453360 @default.
• W4327831237 creator A5035764371 @default.
• W4327831237 creator A5036519336 @default.
• W4327831237 creator A5039731482 @default.
• W4327831237 creator A5040291661 @default.
• W4327831237 creator A5041303726 @default.
• W4327831237 creator A5043005301 @default.
• W4327831237 creator A5048152055 @default.
• W4327831237 creator A5048323364 @default.
• W4327831237 creator A5057141317 @default.
• W4327831237 creator A5064744595 @default.
• W4327831237 creator A5065971161 @default.
• W4327831237 creator A5071318705 @default.
• W4327831237 creator A5071515546 @default.
• W4327831237 creator A5076748422 @default.
• W4327831237 creator A5079455826 @default.
• W4327831237 creator A5081328251 @default.
• W4327831237 creator A5084874518 @default.
• W4327831237 creator A5085000841 @default.
• W4327831237 creator A5085532063 @default.
• W4327831237 creator A5086606150 @default.
• W4327831237 creator A5086699695 @default.
• W4327831237 creator A5088672426 @default.
• W4327831237 creator A5089094449 @default.
• W4327831237 creator A5089767596 @default.
• W4327831237 date "2023-04-01" @default.
• W4327831237 modified "2023-10-18" @default.
• W4327831237 title "Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial" @default.
• W4327831237 cites W1590751877 @default.
• W4327831237 cites W1964167714 @default.
• W4327831237 cites W2029937974 @default.
• W4327831237 cites W2038537430 @default.
• W4327831237 cites W2049112623 @default.
• W4327831237 cites W2058715013 @default.
• W4327831237 cites W2081612366 @default.
• W4327831237 cites W2095204955 @default.
• W4327831237 cites W2108579179 @default.
• W4327831237 cites W2144903426 @default.
• W4327831237 cites W2156747165 @default.
• W4327831237 cites W2174060479 @default.
• W4327831237 cites W2286082361 @default.
• W4327831237 cites W2417116815 @default.
• W4327831237 cites W2596939656 @default.
• W4327831237 cites W2748317794 @default.
• W4327831237 cites W2790247068 @default.
• W4327831237 cites W2901153803 @default.
• W4327831237 cites W2912245259 @default.
• W4327831237 cites W2915034096 @default.
• W4327831237 cites W2956085327 @default.
• W4327831237 cites W2977748898 @default.
• W4327831237 cites W3019135930 @default.
• W4327831237 cites W3032975667 @default.
• W4327831237 cites W3108196093 @default.
• W4327831237 cites W3116072604 @default.
• W4327831237 cites W3133627976 @default.
• W4327831237 cites W3178284862 @default.
• W4327831237 cites W4238898630 @default.
• W4327831237 doi "https://doi.org/10.1016/j.eclinm.2023.101912" @default.
• W4327831237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36969345" @default.
• W4327831237 hasPublicationYear "2023" @default.
• W4327831237 type Work @default.
• W4327831237 citedByCount "0" @default.
• W4327831237 crossrefType "journal-article" @default.
• W4327831237 hasAuthorship W4327831237A5002278563 @default.
• W4327831237 hasAuthorship W4327831237A5003846337 @default.
• W4327831237 hasAuthorship W4327831237A5005879554 @default.
• W4327831237 hasAuthorship W4327831237A5012262637 @default.
• W4327831237 hasAuthorship W4327831237A5012318863 @default.
• W4327831237 hasAuthorship W4327831237A5013215019 @default.
• W4327831237 hasAuthorship W4327831237A5013790590 @default.
• W4327831237 hasAuthorship W4327831237A5015964057 @default.
• W4327831237 hasAuthorship W4327831237A5018284836 @default.
• W4327831237 hasAuthorship W4327831237A5020589345 @default.
• W4327831237 hasAuthorship W4327831237A5022150988 @default.
• W4327831237 hasAuthorship W4327831237A5024408755 @default.
• W4327831237 hasAuthorship W4327831237A5028771001 @default.
• W4327831237 hasAuthorship W4327831237A5031453360 @default.
• W4327831237 hasAuthorship W4327831237A5035764371 @default.
• W4327831237 hasAuthorship W4327831237A5036519336 @default.
• W4327831237 hasAuthorship W4327831237A5039731482 @default.
• W4327831237 hasAuthorship W4327831237A5040291661 @default.
• W4327831237 hasAuthorship W4327831237A5041303726 @default.
• W4327831237 hasAuthorship W4327831237A5043005301 @default.

• next